Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
QuintilesIMS
US Department of Justice
Moodys
Chubb
AstraZeneca
Julphar

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,803,376

« Back to Dashboard

Which drugs does patent 6,803,376 protect, and when does it expire?

Patent 6,803,376 protects FACTIVE and is included in one NDA.

This patent has thirteen patent family members in twelve countries.
Summary for Patent: 6,803,376
Title: Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
Abstract:This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
Inventor(s): Appelbaum; Peter C. (Hershey, PA), Credito; Kim L. (Hershey, PA), Davies; Todd (Hershey, PA), Hoellman; Diane B. (Hershey, PA), Kelly; Linda M. (Hershey, PA), Pankuch; Glenn A. (Hershey, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/569,648
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,803,376

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA ➤ Sign Up
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,803,376

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,331,550 Methods of use of quinolone compounds against anaerobic pathogenic bacteria ➤ Sign Up
6,340,689 Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria ➤ Sign Up
6,455,540 Methods of use of quinolone compounds against anaerobic pathogenic bacteria ➤ Sign Up
6,262,071 Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
McKesson
Merck
US Department of Justice
Teva
Fish and Richardson
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.